No Detail Found!

Expression of JAK2 V617F Mutation in BCR-ABL negative myeloproliferative neoplasms

Author(s)
Kehkashan Hassan Department of Hematology, Armed Forces Institute of Pathology (AFIP),Rawalpindi,Pakistan
Ayesha Khursheed Department of Hematology, Armed Forces Institute of Pathology (AFIP),Rawalpindi,Pakistan
Hamid Saeed Malik Department of Hematology, Armed Forces Institute of Pathology (AFIP),Rawalpindi,Pakistan
Manzar Bozdar Department of Hematology, Armed Forces Institute of Pathology (AFIP),Rawalpindi,Pakistan
Rafia Mahmood Department of Hematology, Armed Forces Institute of Pathology (AFIP),Rawalpindi,Pakistan
Zara Tasneem Department of Hematology, Armed Forces Institute of Pathology (AFIP),Rawalpindi,Pakistan
Abstract
Objective: To detect the presence of JAK2V617F mutation in BCR-ABL negative myeloproliferative neoplasms and to stratify high risk patients for targeted therapy. Methodology: This cross-sectional study was conducted in the Department of Hematology, Armed Forces Institute of Pathology (AFIP), Rawalpindi, from Dec 2023 to Oct 2023. A total of 40 consecutive patients of BCRABL1 negative myeloproliferative disorders, diagnosed according to WHO defined hematological criteria for each disorder, were included in the study. Informed consent and ethical approval were obtained from each individual. Bone marrow aspiration and biopsy was done by aseptic technique. All patients had their blood samples examined for the G-T point mutation (V617F) in the JAK2 gene located on chromosome 9, utilizing allele-specific real-time qualitative polymerase chain reaction (RT-qPCR). Results were entered and analyzed on SPSS version 22. Results: Out of total 40 patients included in our study, 21(52.5%) were diagnosed as Polycythemia Vera (PV), 15 (37.5%) as Primary myelofibrosis (PMF) and 4 (10%) were diagnosed as essential thrombocythemia (ET). JAK2 mutation was found in 20 (95.2%) patients of PV, 9 (60%) patients of PMF and 2 (50%) patients of ET with a significant p-value of ? 0.017. Conclusion: JAK2 V617F is a useful clinical marker for establishing diagnosis andseparating high risk patients for specific targeted therapy.
Publication Details
Page(s) 317-323
Published Journal: Journal of Islamabad Medical & Dental College, Volume: 12, Issue: 4, Year: 2023

Request the full text from PASTIC

Keywords
polycythemia vera, Myeloproliferative neoplasms, Essential thrombocythemia, Primary myelofibrosis.
0

Citations

0

Downloads

132

Views